Search

Vicharchika (Eczema) is a type of kshudrakustha often encountered by Ayurvedic Dermatologists characterized with symptoms, namely, kandu (itching), srava (discharge), Pidaka (vesicles), and Shyava varna (discoloration). Vicharchika is often correlated to eczema based on the clinical presentations. No satisfactory treatment is available in contemporary medical practice except antihistamines and topical steroids. Main line of treatment for vicharchika in Ayurveda is Shodhana and shaman oushadhis. A patient approached to outpatient department with chief complaints of discharge, edema, and erythematous skin lesions with intense itching at the ankles and dorsum of both foot, dorsal aspect of the hands, and on cheeks was treated with Virechana and few Agada preparations. A remarkable improvement in the condition was observed in a span of 2 months.

Background: Asthma is chronic airway inflammatory disorder hallmarked with altered tracheo-bronchial response. WHO estimated three hundred million people suffer from Asthma all over the world and several medicines are available. In Ayurveda, the ancient system of Medicinal Science, this condition is well narrated and treatment offered is Dushivishari Agada (DVA) in powdered form. Methodology: In this study we evaluated the effect of DVA in allergic asthma by experimentally inducing it in wistar rats. Animals were divided into four groups. Normal group (G I) was given orally normal saline for sensitization. In three experimental groups (G II, G III, G IV), asthma was induced by sensitizing with intra-peritoneal Ovalbumin (OVA) and aluminium hydroxide and after 15 days they were challenged with OVA-PBS (Phosphate buffer solution) aerosols for 8 consecutive days. Animals in G II served as asthma control while G III and IV received DVA (250 mg) and Dexamethasone DXM (10 mg/kg) respectively. In blood total and differential count, absolute eosinophil count (AEC), Serum IgE was done. Cellular count was done in Broncho-alveloar lavage fluid (BALF) and lungs underwent histological analysis. Results: DVA significantly reduced serum IgE (3.33 ± 1.08), AEC (145 ± 81.27) and inflammatory cells in BALF when compared to G II [Serum IgE (14.17± 1.16) and AEC (379.2 ± 206.4)] and was in comparison with G IV [Serum IgE(4.017±0.68), AEC(50±38.73)] Conclusion: DVA has shown immune-modulatory effect by bringing down inflammation in allergic bronchial asthma.

Background: Asthma is chronic airway inflammatory disorder hallmarked with altered tracheo-bronchial response. WHO estimated three hundred million people suffer from Asthma all over the world and several medicines are available. In Ayurveda, the ancient system of Medicinal Science, this condition is well narrated and treatment offered is Dushivishari Agada (DVA) in powdered form. Methodology: In this study we evaluated the effect of DVA in allergic asthma by experimentally inducing it in wistar rats. Animals were divided into four groups. Normal group (G I) was given orally normal saline for sensitization. In three experimental groups (G II,G III,G IV), asthma was induced by sensitizing with intra-peritoneal Ovalbumin (OVA) and aluminium hydroxide and after 15 days they were challenged with OVA-PBS (Phosphate buffer solution) aerosols for 8 consecutive days. Animals in G II served as asthma control while G III and IV received DVA (250 mg) and Dexamethasone DXM (10mg/kg) respectively. In blood total and differential count, absolute eosinophil count (AEC), Serum IgE was done. Cellular count was done in Broncho-alveloar lavage fluid (BALF) and lungs underwent histological analysis. Results: DVA significantly reduced serum IgE (3.33 ± 1.08), AEC (145 ± 81.27) and inflammatory cells in BALF when compared to G II [Serum IgE (14.17± 1.16) and AEC (379.2 ± 206.4)] and was in comparison with G IV [Serum IgE (4.017± 0.68), AEC (50 ± 38.73)] Conclusion: DVA has shown immune-modulatory effect by bringing down inflammation in allergic bronchial asthma.